This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Mary Jane Gore
Extract
Trends and Technology welcomes releases and information about new products, services, Web sites, trends, and upcoming events (give us six months lead time for seminars and meetings). If your company has a Website that you would like for us to review, please send us news for our Online section, or tell us about sites that would interest clinical laboratory scientists. These sites, as well as the new product information, are offered for reader information only. We cannot vouch for them and their presence here does not constitute an endorsement by CLS or ASCLS.
FDA APPROVALS Dade Behring has received clearance from the U.S. Food and Drug Administration (FDA) for use of its N High Sensitivity CRP assay as an independent risk marker for the identification of individuals at risk for future cardiovascular disease, i.e., risk assessment. When used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, N High Sensitivity CRP measurements may also be useful as an independent marker of prognosis of recurrent events in patients with stable coronary disease or acute coronary syndromes, i.e., risk stratification. An expert panel of the Centers for Disease Control and Prevention concluded that for patients with stable coronary disease or acute coronary syndromes, high sensitivity CRP measurement may be useful as an independent marker for assessing likelihood of recurrent events. For more information, contact Melissa Ziriakus (847) 236-7038.
NEW PRODUCTS Quantimetrix Corporation releases GlycoHemosure, its new hemoglobin A1c control. This control is intended as a reference material for the monitoring…
- © Copyright 2004 American Society for Clinical Laboratory Science Inc. All rights reserved.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.